Autopsy report · NCT05251727

Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.

“Business Decision”

The sponsor’s own words in the registry.

Life of this trial

Registered 3 months before it started.
Ran for about 2 years 2 months before it stopped.
77 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1
Sponsor: Veloxis Pharmaceuticals
Sponsor type: Industry
Conditions: Chemotherapy-induced Peripheral Neuropathy
Interventions: thrombomodulin alfa; Placebo
Participants: 77
Sites: 32
Countries: Japan, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.